Navigation Links
Alzheimer's drug developer lands $1.2M in venture funding

Madison, Wis. - Mithridion, Inc., a biopharmaceutical start up that is developing drugs to disrupt the progress of Alzheimer's disease, has closed an additional $1.2 million of Series A funding led by Madison's Venture Investors.

The latest round of funding brings the total equity capital raised in th......

Full article >>> s, and the continued support of WARF and Rosetta Partners.

"It's a great leap forward for our company in getting Venture Investors, a professional investment firm," Twose said. "It's not only a leap forward in terms of getting the funding, it's the quality of the investors they bring in."

The new funding will be used to advance Mithridion's drug lead, a prototype drug that will b......

Full article >>> ts discovery is based on animal models used in Alzheimer's research. "It was noted that they [the animals] did not develop the full form of Alzheimer's, which caused investors to ask why?" Neis said.

......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 04/17/07


Related biology technology :

1. Biotech firm has strokes, Alzheimers in its sights
2. Mithridion wins grants for Alzheimers research
3. Alzheimers drug firm and more winners named in Wisconsin business-plan contest
4. Alzheimers drug market to hit $5.5 billion by 2009, study says
5. Marshfield study mixes DNA into electronic medical record to screen for Alzheimers
6. UW Alzheimers researchers found company; privacy law; Science Expeditions
7. Madison-based Mithridion seeks to capitalize on Alzheimers breakthrough
8. Discovery may halt progression of Alzheimers
9. Milwaukee software developer gains bottom line, loses waistline
10. Emerging game developer begins work on prototypes
11. Metavante to buy California software developer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/16/2017)... , February 16, 2017 ... infusion of innovative telemedicine application, new and leading ... are experiencing a boom worldwide. The healthcare sector ... of technologies, services and new therapies for companies ... (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
(Date:2/16/2017)... 16, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, today announced it ... and entered into a $5 million credit facility ... use the capital for general corporate purposes to ... the treatment of serious diseases treated by dermatologists. ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today the ... Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial ... physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative ...
(Date:2/16/2017)... , Feb. 16, 2017  Rhythm, ... rare genetic deficiencies that result in life-threatening ... a $41 million mezzanine round of financing ... OrbiMed, MPM Capital, New Enterprise Associates, Pfizer ... undisclosed public healthcare investment fund. Rhythm will ...
Breaking Biology Technology:
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
Breaking Biology News(10 mins):